Tassos Gianakakos
Co-founder, Chief Executive Officer and Chair @ Kardigan
United States
Menlo Park
Biotechnology
-
Experience

Co-founder, Chief Executive Officer and Chair
Prolaio is a connected platform for heart care, driving optimal treatment plans and outcomes, and helping new therapies reach patients more safely, through continuous remote monitoring, AI-powered predictive analytics, and intuitive, workflow-based user experiences.

Chief Executive Officer
Brisbane, California, United States
MyoKardia pioneered a precision medicine approach to discovering and developing novel therapies for heart conditions. Its lead medicine, Camzyos® (mavacamten) was approved by the FDA in April of 2022 for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the first approved cardiac myosin inhibitor. MyoKardia was acquired by BMS in November of 2020.
Tassos Gianakakos's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.









